Totus Medicines

Totus Medicines is a private, preclinical-to-clinical stage biotech founded in 2019 and headquartered in Cambridge, Massachusetts. The company leverages its proprietary OmniDEL platform—which combines ultra-high-throughput cell-based screening of covalent libraries with AI/ML-powered drug design—to develop oral covalent inhibitors against validated but poorly drugged or previously undruggable targets. Its lead asset, TOS-358, is a covalent PI3Kα inhibitor in Phase 1 trials for oncology, with a discovery program targeting IRF5 in immunology and inflammation. Totus represents a convergence of covalent chemistry, functional genomics, and machine learning aiming to unlock new therapeutic modalities.

OmniDEL platform: an integrated discovery engine combining an evolving covalent chemistry library, ultra-high-throughput cell-based screening with proprietary tagging, and AI/ML-powered drug design to identify and optimize covalent small molecules against undruggable targets.

In oncology, TOS-358 competes with other PI3Kα inhibitors (e.g., alpelisib) and mutant-selective candidates, where tolerability is a key differentiator. In immunology, targeting IRF5 is a novel approach with no direct competitors, but success requires pioneering a new drug class against a high-risk target.